Optiscan has been featured in Stockhead in an article recognising ASX companies advancing breast cancer care during Global Breast Cancer Awareness Month.

The story highlights how Optiscan has pioneered the world’s first miniaturised confocal microscope that allows doctors, pathologists and veterinarians to see living tissue at sub-cellular resolution in real-time.

By delivering slide-free, biopsy-free, high-resolution microscopic imaging, Optiscan aims to identify cancer cells instantly, enabling faster, more accurate treatment decisions and reduce the need for invasive procedures.

In June, Optiscan started its ground-breaking first in-human breast cancer study at the Royal Melbourne Hospital, which will recruit 50 patients undergoing breast-conserving procedures. The study is evaluating how Optiscan’s InVue™ device can assist surgeons in assessing tissue during breast-conserving surgery, and how its companion digital pathology device InForm™ can support pathologists in examining tissue immediately after it is removed.

Together, these technologies aim to create a fully digital surgical-pathology process that could help reduce repeat operations, shorten waiting times for results and improve patient outcomes.

"Being able to evaluate tumour margins with cellular-level precision during surgery has the potential to revolutionise breast cancer treatment,” said Dr. Camile Farah, Optiscan CEO.

“By providing surgeons with direct, live imaging of cellular structures, we’re setting a new standard for precision and patient-centred care in oncology.”

Stockhead – Read the full article here.